Quest Diagnostics is teaming up with France's national health agency to create an expanded database for breast and ovarian cancer gene research, allowing diagnostics outfits and labs to sift through a trove of genetic information to improve outcomes for patients.
Liquid biopsy tests are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. A recent report by financial services firm Cowen & Co. said annual sales for the tools could surpass $10 billion, and study results are also turning up positive data in favor of the tests. Read more >>
Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D. Read more >>
POPULAR COMMENT THREADS
Point-of-care diagnostics are picking up steam in the industry, with companies rolling out mobile platforms and smartphone apps that can quickly identify diseases. VisualDx is taking a different approach, offering a quick diagnostic tool that uses images rather than text to help physicians screen for certain conditions. Read more >>
Veracyte is selling $40 million of its common stock in a private placement to generate some cash for R&D, adding fuel to its engine as it inks new deals and looks to expand its portfolio.
Roche is not wasting any time after sealing its $1.2 billion deal for Foundation Medicine, charging full speed ahead with the companies' planned cancer R&D collaboration to generate growth in the coming year.
Science is rapidly shaping the landscape of the diagnostics industry, from the research into genetics and new materials like graphene, to the regulatory science practiced at the FDA.
California genetic testing firm Color Genomics launched its $249 spit test kit for breast and ovarian cancer, making its foray into a crowded BRCA market.
The federal antitrust watchdog came down hard on Dublin, OH's Cardinal Health for allegedly monopolizing the market for certain radiation-emitting diagnostics for heart disease. Cardinal Health agreed to pay a $26.8 million fine to the Federal Trade Commission to compensate injured patients, in what is the second largest settlement the commission has obtained in an antitrust case.
From Our Sister Sites
It has taken more than a year to get its manufacturing problems, and lozenges, back into shape and shipped, but GlaxoSmithKline says some Nicorette Lozenges are back on retailer shelves. That is particularly good news for those former smokers who have substituted a Nicorette habit for a smoking one.
Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts.